Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALYSSA B BRZENSKI

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1740470673
CMS profile
1124849
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$148.51

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $148.51 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ACACIA PHARMA INC $148.51 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALYSSA B BRZENSKI

NPI 1740470673 · CMS profile ID 1124849

Allopathic & Osteopathic Physicians / Anesthesiology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740470673?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALYSSA B BRZENSKI, NPI 1740470673, CMS profile ID 1124849. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740470673?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ALYSSA B BRZENSKI, NPI 1740470673, CMS profile ID 1124849. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740470673?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ALYSSA B BRZENSKI, NPI 1740470673, CMS profile ID 1124849, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1740470673?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $148.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ACACIA PHARMA INC $148.5110/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937465079 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $920.31 10
PY2022 $148.51 1
PY2023 $251.00 2
PY2024 $95.44 1
PY2025 $121.84 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $3,575.00 1
PY2019 Principal investigator $49,620.83 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $8,507.80 12/18/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691469351
Principal investigator 1 Merck Sharp & Dohme Corporation $391.14 11/12/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691510563
Principal investigator 1 Merck Sharp & Dohme Corporation $134.68 11/12/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691518495
Principal investigator 1 Merck Sharp & Dohme Corporation $15,170.00 11/04/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691502485
Principal investigator 1 Merck Sharp & Dohme Corporation $3,250.00 10/30/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691429381
Principal investigator 1 Merck Sharp & Dohme Corporation $9,159.80 10/25/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691429385
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 10/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691538957
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 10/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691538985
Principal investigator 1 Merck Sharp & Dohme Corporation $1.56 10/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691539295
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 10/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691539491
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 10/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691539495
Principal investigator 1 Merck Sharp & Dohme Corporation $3.45 10/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691541243
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 09/12/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691424709
Principal investigator 1 Merck Sharp & Dohme Corporation $0.52 09/10/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462003
Principal investigator 1 Merck Sharp & Dohme Corporation $0.92 09/10/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462007
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 09/10/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462054
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691430975
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691431729
Principal investigator 1 Merck Sharp & Dohme Corporation $4.14 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691459955
Principal investigator 1 Merck Sharp & Dohme Corporation $6.84 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691459959
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462045
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462049
Principal investigator 1 Merck Sharp & Dohme Corporation $118.80 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462169
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462173
Principal investigator 1 Merck Sharp & Dohme Corporation $12.24 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462389
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462393
Principal investigator 1 Merck Sharp & Dohme Corporation $2.08 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462581
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462585
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462589
Principal investigator 1 Merck Sharp & Dohme Corporation $3.08 08/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691462593
Principal investigator 1 Merck Sharp & Dohme Corporation $35.85 04/16/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691344455
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 04/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691424635
Principal investigator 1 Merck Sharp & Dohme Corporation $758.88 04/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691425907
Principal investigator 1 Merck Sharp & Dohme Corporation $391.14 04/08/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691431741
Principal investigator 1 Merck Sharp & Dohme Corporation $10,000.00 03/27/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691320883
Principal investigator 1 Merck Sharp & Dohme Corporation $13.50 03/07/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691344223
Principal investigator 1 Merck Sharp & Dohme Corporation $318.49 02/11/2019 Covered Recipient Teaching Hospital
RADY CHILDRENS HOSPITAL - SAN DIEGO
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691346331